Sensitive skin is one of the most widespread concerns in the world. Between 60 to 70 per cent of women and 50 to 60 per cent of men say they suffer from some degree of skin sensitivity.
Galderma, the maker of Cetaphil, Benzac and Differin anti-acne treatments and Dysport and Restylane injectables, has formed a new world-first global community to address the issue and promote further research.
The faculty expert group will focus on innovations and management to help people with sensitive skin better understand and cope with the problem.
Thirteen international experts from Australia, the US, China, Brazil, the Phillipines, Italy, Germany and France will lend their expertise.
Dr Belinda Welsh, the distinguished specialist dermatologist, is the Australian member of the group. She is senior vice president of The Australasian Society of Cosmetic Dermatologists and has her own practice in Melbourne – Complete Skin Specialists.
Dr Welsh has also worked in the public health system for many years, including The Alfred Hospital, St Vincent’s Hospital, Mercy Hospital for Women and The Royal Children’s Hospital laser clinic.
An in-demand speaker at conferences globally, she is also the Associate Editor of the Australasian Journal of Dermatology.
We want people to feel in control of their skin, and this is especially important for those who have skin conditions that are often misunderstood like sensitive skin, notes Walter Geiger, consumer global business unit head for Galderma.
“We’re delighted to bring together such an esteemed group of experts from around the world who will collaborate to propose and implement research, innovation and educational projects to advance the science of sensitive skin and bring positive changes to the whole community.”
Read the current issue of our digital magazine below:
- For more news and updates, subscribe to our weekly newsletter
- Follow us on Instagram
- Like us on Facebook
- Connect with us on LinkedIn